<?xml version='1.0' encoding='utf-8'?>
<document id="19575604"><sentence text="Metabolic interactions between prokinetic agents domperidone and erythromycin: an in vitro analysis."><entity charOffset="49-60" id="DDI-PubMed.19575604.s1.e0" text="domperidone" /><entity charOffset="65-77" id="DDI-PubMed.19575604.s1.e1" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.19575604.s1.e0" e2="DDI-PubMed.19575604.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19575604.s1.e0" e2="DDI-PubMed.19575604.s1.e1" /></sentence><sentence text="This study examined in vitro interaction between domperidone and erythromycin"><entity charOffset="49-60" id="DDI-PubMed.19575604.s2.e0" text="domperidone" /><entity charOffset="65-77" id="DDI-PubMed.19575604.s2.e1" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.19575604.s2.e0" e2="DDI-PubMed.19575604.s2.e0" /><pair ddi="false" e1="DDI-PubMed.19575604.s2.e0" e2="DDI-PubMed.19575604.s2.e1" /></sentence><sentence text=" Both are prescribed for refractory gastroparesis" /><sentence text=" Domperidone is metabolized via human cytochrome P4503A4"><entity charOffset="1-12" id="DDI-PubMed.19575604.s4.e0" text="Domperidone" /></sentence><sentence text=" Erythromycin is a CYP3A4 inhibitor"><entity charOffset="1-13" id="DDI-PubMed.19575604.s5.e0" text="Erythromycin" /></sentence><sentence text=" Incubations evaluated domperidone metabolite formation in human liver microsomes and recombinant CYP3A4"><entity charOffset="23-34" id="DDI-PubMed.19575604.s6.e0" text="domperidone" /></sentence><sentence text=" Concentration- and time-dependent inhibition of 500 microM domperidone was studied with 2"><entity charOffset="60-71" id="DDI-PubMed.19575604.s7.e0" text="domperidone" /></sentence><sentence text="5-200 microM erythromycin over 10-40 min"><entity charOffset="13-25" id="DDI-PubMed.19575604.s8.e0" text="erythromycin" /></sentence><sentence text=" Domperidone metabolite (5-hydroxy domperidone, M3) formation was inhibited by erythromycin in a concentration- and time-dependent manner"><entity charOffset="1-12" id="DDI-PubMed.19575604.s9.e0" text="Domperidone" /><entity charOffset="25-46" id="DDI-PubMed.19575604.s9.e1" text="5-hydroxy domperidone" /><entity charOffset="79-91" id="DDI-PubMed.19575604.s9.e2" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.19575604.s9.e0" e2="DDI-PubMed.19575604.s9.e0" /><pair ddi="false" e1="DDI-PubMed.19575604.s9.e0" e2="DDI-PubMed.19575604.s9.e1" /><pair ddi="false" e1="DDI-PubMed.19575604.s9.e0" e2="DDI-PubMed.19575604.s9.e2" /><pair ddi="false" e1="DDI-PubMed.19575604.s9.e1" e2="DDI-PubMed.19575604.s9.e1" /><pair ddi="false" e1="DDI-PubMed.19575604.s9.e1" e2="DDI-PubMed.19575604.s9.e2" /></sentence><sentence text=" The K(I) estimate was 18" /><sentence text="4 microM in human liver microsomes and 4" /><sentence text="1 microM in CYP3A4" /><sentence text=" Using a model incorporating CYP3A4 hepatic and gut inhibition, in vitro estimates from human liver microsomes and CYP3A4 were used to predict in vivo AUCi/AUC ratios of 2" /><sentence text="54 and 4" /><sentence text="95, respectively" /><sentence text=" Significant inhibition of domperidone metabolism by erythromycin occurs"><entity charOffset="27-38" id="DDI-PubMed.19575604.s16.e0" text="domperidone" /><entity charOffset="53-65" id="DDI-PubMed.19575604.s16.e1" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.19575604.s16.e0" e2="DDI-PubMed.19575604.s16.e0" /><pair ddi="false" e1="DDI-PubMed.19575604.s16.e0" e2="DDI-PubMed.19575604.s16.e1" /></sentence><sentence text=" This predicts greater domperidone drug exposure when used with erythromycin"><entity charOffset="23-34" id="DDI-PubMed.19575604.s17.e0" text="domperidone" /><entity charOffset="64-76" id="DDI-PubMed.19575604.s17.e1" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.19575604.s17.e0" e2="DDI-PubMed.19575604.s17.e0" /><pair ddi="false" e1="DDI-PubMed.19575604.s17.e0" e2="DDI-PubMed.19575604.s17.e1" /></sentence><sentence text=" This important drug-drug interaction will be evaluated in future human studies" /><sentence text="" /></document>